Shrikanta Chattopadhyay is an Oncology physician affiliated with TScan Therapeutics. OpenAlex indexes 56 publications with 4,296 citations (h-index 21); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Telephone
617-643-1737Registry record last updated 8 Jul 2007.
Clinical trials
- A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Sponsor: TScan Therapeutics, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
1 NIH research award on record, funded 2011–2015 per NIH RePORTER. The latest:
- Targeting Metastasis Induced by Mesenchymal Stem Cells in the Tumor Stroma
Massachusetts General Hospital
FY2015$178,015K08CA158149 - Targeting Metastasis Induced by Mesenchymal Stem Cells in the Tumor Stroma
Massachusetts General Hospital
FY2014$178,015K08CA158149 - Targeting Metastasis Induced by Mesenchymal Stem Cells in the Tumor Stroma
Massachusetts General Hospital
FY2013$178,015K08CA158149
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910)
Biology of Blood and Marrow Transplantation
2025 - Micro-Chimerism Detected By Highly Sensitive AlloHemeTM Solution Is Associated with Treatment Response and Relapse after Allogeneic Stem Cell Transplantation
Biology of Blood and Marrow Transplantation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”